Please ensure Javascript is enabled for purposes of website accessibility

How Zimmer Biomet Holdings Beat Expectations in Q4

By Keith Speights – Feb 4, 2020 at 12:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's hip and knee replacement products continue to enjoy solid demand.

Zimmer Biomet Holdings (ZBH -0.31%) delivered a sizzling performance in 2019, with shares soaring 44%. But 2020 started off flat -- the medical device stock traded essentially sideways through January.

That could change now. Zimmer Biomet announced its 2019 fourth-quarter and full-year results before the market opened on Tuesday. Here are the highlights from the company's update.

Man holding tablet with numbers projecting out

Image Source: Getty Images.

By the numbers

Zimmer Biomet reported fourth-quarter revenue of $2.13 billion, up 2.6% year over year. That topped analysts' average prediction of $2.11 billion. Net income was $321.4 million, or $1.54 per share, based on generally accepted accounting principles (GAAP). That was a considerable improvement from the GAAP net loss of $902.5 million, or $4.42 per share, in the prior-year period.

The company's adjusted net income was $2.30 per share, up from $2.18 per share in Q4 2018. Zimmer Biomet's adjusted earnings also easily beat the consensus Wall Street estimate of $2.27 per share.

Behind the numbers

Foreign exchange fluctuations hurt Zimmer Biomet somewhat in the fourth quarter. The company stated on a constant currency basis, its revenue climbed 3.2% year over year, well above the reported 2.6% increase.

Over 60% of Zimmer Biomet's total revenue comes from the Americas region, where fourth-quarter sales rose 2.3% to $1.29 billion. The growth picture looked even better in the Asia Pacific region, where sales jumped 9.2% to $367 million. However, Europe was a weak spot  -- sales there slipped by 1.1% to $471 million.

The company reported 4.9% year-over-year sales growth for its knee-replacement products and 3.2% growth for its hip-replacement products. Management noted that sales of the ROSA Knee System  picked up momentum from Q3, and also said that the Q4 launches of the Persona Revision knee system and Avenir Complete hip system went well.

Zimmer Biomet's restructuring initiatives made a big impact. Operating expenses in Q4 were down 37% from the prior-year quarter to $1.79 billion. Those cost reductions combined with revenue growth led to significant improvement on the bottom line.

Looking ahead

Management forecast that revenue will increase by between 2.5% and 3.5% in 2020, and projected adjusted diluted earnings per share of between $8.15 and $8.45.

Some healthcare stocks could experience significant volatility over the next year as the future of the U.S. healthcare system is debated in the presidential campaign. Other companies could run into challenges related to the coronavirus outbreak, with travel restrictions and business shutdowns in China cause problems. The latter could be more of an issue for Zimmer Biomet because of its Asian segment. However, CEO Bryan Hanson said that the company is "operating from a position of strength for 2020 and beyond." 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zimmer Biomet Holdings, Inc. Stock Quote
Zimmer Biomet Holdings, Inc.
ZBH
$104.82 (-0.31%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.